Our partner is a biotech company that applies its Disease Interrogator platform to improve drug discovery for pharmaceutical and biotechnology partners. Their platform integrates soft lithography, surface chemistry, cell biology and algorithms to open windows into human disease by providing researchers with living microenvironments using human cells to advance invitro models of disease.

This critical hire led research efforts and managed over 30 preclinical GLP studies for 3 candidate molecules to support the filing of multiple CTAs or INDs to U.S. and European authorities. They executed relevant regulatory filing efforts and played a key role in the design of multiple Phase Ia to Phase IIb clinical protocols in the areas of metabolic and cardiovascular disease.